BIOGEN INC. (BIIB)

Biogen is a global biopharmaceutical company that discovers, develops and delivers therapies for serious and complex diseases, with a broad portfolio of multiple sclerosis medicines and treatments for SMA, Alzheimer's disease and ALS.

TickerBIIB
CompanyBIOGEN INC.
ExchangeNasdaq
HeadquartersCAMBRIDGE, MA

Income statement — period ending 2026-06-30

BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1$2,500
CostOfGoodsAndServicesSold$776,900
CostOfGoodsAndServicesSold$1,437,900
CostsAndExpenses$2,603,600
CostsAndExpenses$4,703,700
EarningsPerShareBasic1 USD/shares
EarningsPerShareBasic3 USD/shares
EarningsPerShareDiluted1 USD/shares
EarningsPerShareDiluted3 USD/shares
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest$132,400
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest$510,100
IncomeTaxExpenseBenefit$34,900
IncomeTaxExpenseBenefit$93,100
NetIncomeLoss$97,500
NetIncomeLoss$417,000
OtherOperatingIncomeExpenseNet$18,500
OtherOperatingIncomeExpenseNet$38,200
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost$529,600
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost$1,068,600
RestructuringCharges$165,400
RestructuringCharges$173,300
Revenues$242,400
Revenues$489,300
SellingGeneralAndAdministrativeExpense$709,700
SellingGeneralAndAdministrativeExpense$1,317,000
WeightedAverageNumberOfDilutedSharesOutstanding$148,700,000
WeightedAverageNumberOfDilutedSharesOutstanding$148,600,000
WeightedAverageNumberOfSharesOutstandingBasic$147,700,000
WeightedAverageNumberOfSharesOutstandingBasic$147,400,000

Sourced from SEC EDGAR/XBRL filings via StockSpectro.

View full interactive research on StockSpectro